CGON Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 20.76%, SMA50 27.32%, SMA200 67.15%). The stock’s 14-day RSI is 70.48 (overbought), while the ATR of 3.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.71% below its high and over 269.53% above its low. Average 10-day trading volume of 1.11 million shares is slightly above the 3-month average of 991.25 thousand, indicating heightened recent market interest.

Wall Street analysts project EPS growth of -17.75% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $90.00 to $47.00. The high target offers 64.56% upside. The low target suggests -14.06% downside. The mean target is $66.90. This offers 22.33% upside. CG Oncology, Inc. Common stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in August 08, 2024.

CG Oncology, Inc. Common stock has 80.67 million shares outstanding. The public float is 65.44 million shares, elevated short interest at 17.28% of float. This equals 13.21 million shares. The short ratio is 14.15 days. Institutional investors hold 113.95% of the float. Insiders own 1.17%. Song Hong Fang holds 2.90 million shares, Liu Brian Guan-Chyun has 1.52 million shares and Decheng Capital Global Life Sciences Fund IV, L.P. has 400.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 64.05 thousand shares across 12 transactions.

CG Oncology, Inc. Common stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.86. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that CG Oncology, Inc. Common stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.52%, with price expected at $64.82 by February 03, 2026, within a range of $61.42 to $68.02 3-Month Outlook: Projected fall of -29.82%, reaching $38.38 by April 16, 2026, with a range of $36.37 to $40.28. 1-Year Outlook: Projected gain of 1.19%, with price at $55.34 by January 15, 2027, within a range of $52.61 to $57.78.

CG Oncology, Inc. Common stock (NASDAQ:CGON) shares are up 31.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CG Oncology, Inc. Common stock trading at a premium to the broader market with a P/E of -27.46. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $67.65, suggesting 23.7% upside. Our AI forecast model points to short-term strength (18.52% over two weeks), a medium-term fall (-29.82% over three months), and a longer-term gain (1.19% over one year), with expected trading ranges indicating moderate volatility.

CG Oncology, Inc. Common stock trades at a P/E ratio of -27.46, slightly below the S&P 500 average, with a price-to-sales ratio of 2011.46 and a price-to-book ratio of 6.05 trading at moderately above to book value. The P/FCF stands at -37.33, also below market averages.